Recent genomic and transcriptomic analyses of diffuse large B cell lymphoma (DLBCL) have provided important new insights into the heterogeneous biology of this disease. The findings provide opportunities to improve treatment strategies, although considerable work is needed to establish and optimize the clinical applicability and utility of molecular classifications of DLBCL.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Alizadeh, A. A. et al. Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000).
Knittel, G. et al. B cell-specific conditional expression of Myd88p. L252P leads to the development of diffuse large B cell lymphoma in mice. Blood 127, 2732–2741 (2016).
Souroullas, G. P. et al. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nat. Med. 22, 632–640 (2016).
Schmitz, R. et al. Genetics and pathogenesis of diffuse large B cell lymphoma. N. Engl. J. Med. 378, 1396–1407 (2018).
Chapuy, B. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24, 679–690 (2018).
Leonard, J. P., Martin, P. & Roboz, G. J. Practical implications of the 2016 revision of the World Health Organization classification of lymphoid and myeloid neoplasms and acute leukemia. J. Clin. Oncol. 35, 2708–2715 (2017).
Lee, Y. S. et al. Lack of a prognostic impact of the MyD88 L265P mutation for diffuse large B cell lymphoma patients undergoing autologous stem cell transplantation. Biol. Blood Marrow Transplant. 23, 2199–2204 (2017).
Yu, S. et al. High frequency and prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma with R-CHOP treatment. Oncol. Lett. 15, 1707–1715 (2018).
Reddy, A. et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell 171, 481–494 (2017).
Dubois, S. et al. Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P-mutated diffuse large B cell lymphoma: analysis of 361 cases. Clin. Cancer Res. 23, 2232–2244 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Dubois, S., Jardin, F. Novel molecular classifications of DLBCL. Nat Rev Clin Oncol 15, 474–476 (2018). https://doi.org/10.1038/s41571-018-0041-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0041-z
